Plant · Scientific monograph
Curcuma longa
Turmeric
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Inflammatory Pathways, Neurological & Cognitive Research, Cellular & Immune Studies, Oxidative Stress Research
Research overview
Historical use
Curcuma longa has been central to Ayurvedic (Haridra), Unani, and Traditional Chinese Medicine for over 4,000 years. Used in Ayurveda as an anti-inflammatory, wound healer, carminative, and hepatoprotective agent; applied topically for skin diseases and joint pain. Featured in the Sushruta Samhita (c. 600 BCE) and traditional Southeast Asian cooking as both spice and medicine. The yellow pigment curcumin was first isolated in 1815.
Modern research context
Curcumin (the principal bioactive curcuminoid) is one of the most extensively studied phytochemicals. A 2026 comprehensive review confirms regulatory roles on noncoding RNAs, epigenetic modifications, and multiple signalling cascades [1]. Clinical trials demonstrate anti-inflammatory benefit in osteoarthritis, inflammatory bowel disease, and metabolic syndrome. A 2026 RCT evaluated turmeric effects on endothelial function and redox-inflammatory pathways in type 2 diabetes [5]. Poor oral bioavailability of native curcumin — due to rapid metabolism and low aqueous solubility — is a central clinical challenge; enhanced formulations (piperine combinations, nanoparticles, micellar preparations) significantly improve systemic exposure in human bioavailability studies [2, 6]. CYP450-mediated drug interactions represent a clinically significant concern requiring monitoring [3, 8].
Adverse effects
Well-tolerated at doses ≤8 g/day curcumin in clinical trials. Common adverse effects at higher doses: GI discomfort, nausea, diarrhoea, and flatulence. Rare hepatotoxicity with high-dose or adulterated preparations. Curcumin inhibits platelet aggregation, increasing bleeding risk. Yellow staining of skin and mucous membranes at high doses.
Contraindications
Avoid at medicinal doses in biliary tract obstruction and gallstones (stimulates bile secretion). Caution with anticoagulants (warfarin, heparin, DOACs) due to additive antiplatelet effects. CYP3A4/CYP1A2 inhibition risks interactions with narrow therapeutic index drugs (cyclosporine, tacrolimus, certain chemotherapy agents) [3]. Avoid high-dose supplements in pregnancy.
Clinical and phytochemical data
Used part
Rhizome (dried root)
Primary active compounds
Curcumin (diferuloylmethane)
Demethoxycurcumin
Bisdemethoxycurcumin
α-Turmerone (sesquiterpene)
β-Turmerone
ar-Turmerone
Curlone
Mechanism of action
Pleiotropic anti-inflammatory activity through simultaneous inhibition of NF-κB, AP-1, and STAT3 transcription factors, suppressing COX-2, iNOS, and pro-inflammatory cytokine expression [1]. Antioxidant activity via direct free-radical scavenging and Nrf2/HO-1 pathway induction, upregulating glutathione and catalase [6]. Epigenetic modulation — curcumin regulates miRNA expression and acts as a DNMT and HDAC inhibitor [1]. Metabolic effects include AMPK-dependent lipid metabolism regulation and insulin sensitisation [6]. Neuroprotective effects include inhibition of amyloid-β aggregation and tau hyperphosphorylation via GSK-3β inhibition [7].
Pharmacokinetics
Absorption
Oral bioavailability of native curcumin is inherently poor due to rapid intestinal metabolism, low aqueous solubility, and extensive presystemic elimination; peak plasma concentrations after standard doses are typically <10 ng/mL in human pharmacokinetic studies [1]. Enhanced formulations substantially improve systemic exposure: a 2025 randomised comparative human study (Malhotra VK et al.) demonstrated that BioTurm™ achieved significantly enhanced bioavailability versus standard curcumin-piperine combinations without requiring additional enhancers [2]. Nanoparticulate and micellar delivery systems increase Cmax and AUC by 2–10-fold in human subjects [6].
Distribution
Curcumin and its primary metabolites (tetrahydrocurcumin, curcumin glucuronide, curcumin sulfate) distribute to liver, intestine, kidney, and brain [1]. Highly lipophilic; plasma protein binding to albumin and α1-acid glycoprotein exceeds 90%. Blood-brain barrier penetration is supported by neuroprotection data and preclinical models [7].
Metabolism
Extensive first-pass metabolism in the intestinal wall and liver; curcumin undergoes reduction to dihydrocurcumin and tetrahydrocurcumin, followed by phase II glucuronidation and sulfation. CYP3A4, CYP1A2, and CYP2D6 are involved in oxidative metabolism; curcumin concurrently inhibits these enzymes, creating potential for auto-inhibition and drug interactions [3]. Gut microbiota biotransformation generates additional metabolites including ferulic acid [1].
Excretion
Primarily faecal (>60%) as phase II conjugates and degradation products; renal excretion of glucuronide/sulfate metabolites accounts for <10% of absorbed dose. Elimination half-life is approximately 6–8 hours for curcumin metabolites in human pharmacokinetic studies [1, 2].
Safety and interactions
Drug interactions
Curcumin is a potent modulator of drug-metabolising enzymes with clinically significant interaction potential. Inhibition of CYP3A4, CYP1A2, and CYP2D6 raises plasma concentrations of co-administered substrates including cyclosporine, tacrolimus, statins, certain chemotherapy agents, and psychotropics [3, 4]. P-glycoprotein (P-gp) inhibition enhances absorption of efflux transporter substrates (e.g. paclitaxel, digoxin). Additive antiplatelet effects with warfarin, heparin, and direct oral anticoagulants are clinically documented [1]. A 2025 systematic review of curcumin in kidney disease identified multiple curcumin-drug interactions affecting drug bioavailability and clinical efficacy [8]. Patients on narrow therapeutic index drugs or polypharmacy should be monitored closely.
Toxicity
Curcumin holds GRAS status (Generally Recognised as Safe) at food use levels per US FDA classification, applicable to culinary doses — this designation does not extend to suprapharmacological supplement doses. In clinical trials, doses up to 8 g/day are generally tolerated; doses >10 g/day cause dose-dependent GI adverse effects. Rare hepatotoxicity reported with adulterated or high-dose preparations. No mutagenicity or genotoxicity detected in standard assays [1]. Long-term safety data beyond the studied trial durations are limited.
Special precautions
Pregnancy
High-dose medicinal use not recommended. Curcumin may stimulate uterine contractions at pharmacological doses; controlled human data absent. Culinary use is considered safe.
Lactation
Limited data. Culinary use likely safe; medicinal-dose supplements should be avoided.
Hepatic impairment
Use with caution due to extensive hepatic metabolism and rare hepatotoxicity reports with high-dose preparations. Baseline and periodic liver enzyme monitoring recommended.
Renal impairment
Curcumin and metabolites predominantly eliminated via faeces; no specific renal dose adjustment established. Evidence suggests potential nephroprotective benefit in CKD populations [8].
Sources and references
- [1] - Wang Z et al., "Turmeric: A Comprehensive Review.", Nutrients, 2026, PMID: 42075010
- [2] - Malhotra VK et al., "BioTurm™ Bioavailability Study: Randomized comparative study of turmeric extract formulations.", Cureus, 2025, PMID: 41426786
- [3] - Căuș MN et al., "Herbal Supplements Review — cytochrome P450-mediated drug interactions identified for turmeric.", Pharmaceuticals, 2026, PMID: 41901246
- [4] - Bertollo AG et al., "Medicinal plants for major depressive disorder: complex pharmacokinetics and herb-drug interaction risks.", Brain Sciences, 2026, PMID: 41750223
- [5] - Viudes DR et al., "Randomized placebo-controlled study of turmeric on endothelial glycocalyx in type 2 diabetes.", European Journal of Nutrition, 2026, PMID: 41984245
- [6] - Kuzia N et al., "Zingiberaceae plants for antidiabetic and anti-inflammatory use: bioavailability delivery systems.", Molecules, 2026, PMID: 41599361
- [7] - Sneha Sri R et al., "Integration of traditional medicine approaches for Alzheimer's disease: curcumin neuroprotective effects.", Frontiers in Pharmacology, 2025, PMID: 40661073
- [8] - Ofori-Attah E et al., "Systematic review of curcumin in kidney disease: curcumin-drug interactions and bioavailability.", Antioxidants, 2025, PMID: 41300526